Gilead gains FDA approvela for its first cancer drug Zydelig, which will compete against Johnson & Johnson and Pharmacyclics' Imbruvica.
Brian Orelli, The Motley Fool, The Motley Fool
Fri, 07/25/2014 - 5:30am
Gilead gains FDA approvela for its first cancer drug Zydelig, which will compete against Johnson & Johnson and Pharmacyclics' Imbruvica.